Condition: Carcinoma, Non-Small-Cell Lung · Sponsor: University of Colorado, Denver
The purpose of this study is to assess percentage reduction in the of urine NTX and serum CTX , in patients with NSCLC and bone metastases 1) with actionable driver oncogene on standard of care (SOC) TKI at 3 months post treatment and 2) without actionable mutations on standard of care therapy (chemotherapy/immunotherapy) treated with zoledronic acid or denosumab at the same time period.
This description comes directly from the study's public registry record.
Febin Elias · 13037249459 · febin.elias@cuanschutz.edu
Always discuss trial participation with your own doctor first.
| University of Colorado Hospital | Aurora, Colorado, United States | Recruiting |
| Lone Tree Medical Center | Lone Tree, Colorado, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03958565